Cargando…

Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report

Primary liver cancer (PLC) that originates in the liver is a malignant tumor with the worst prognosis. Hepatocellular carcinoma (HCC) is the most common type of PLC. Most PLC cases are diagnosed at advanced stages mainly due to their insidious onset and rapid progression. Patients with PLC undergo s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yun, Zhao, Yan, Li, Miaoling, Hou, Huilian, Jian, Zhijie, Li, Weizhi, Li, Peijie, Ma, Fuquan, Liu, Mengying, Liu, Haibo, Xue, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225497/
https://www.ncbi.nlm.nih.gov/pubmed/37256142
http://dx.doi.org/10.3389/fimmu.2023.1180001
_version_ 1785050385149329408
author Wang, Yun
Zhao, Yan
Li, Miaoling
Hou, Huilian
Jian, Zhijie
Li, Weizhi
Li, Peijie
Ma, Fuquan
Liu, Mengying
Liu, Haibo
Xue, Hui
author_facet Wang, Yun
Zhao, Yan
Li, Miaoling
Hou, Huilian
Jian, Zhijie
Li, Weizhi
Li, Peijie
Ma, Fuquan
Liu, Mengying
Liu, Haibo
Xue, Hui
author_sort Wang, Yun
collection PubMed
description Primary liver cancer (PLC) that originates in the liver is a malignant tumor with the worst prognosis. Hepatocellular carcinoma (HCC) is the most common type of PLC. Most PLC cases are diagnosed at advanced stages mainly due to their insidious onset and rapid progression. Patients with PLC undergo surgical intervention or localized treatment, but their survival is often affected by its high relapse rate. Medical treatment is the primary option for patients with liver cancer, especially with advanced extrahepatic metastases. Molecular targeted therapy exerts an anti-tumor effect by acting on various signaling pathways involved in molecular pathogenesis; however, high drug resistance and low therapeutic responsiveness of PLC to molecular targets challenge the treatment option. In recent years, after surgical intervention, radiotherapy, chemotherapy, and/or molecular targeted therapy, autologous cell immunotherapy has been adopted for PLC. As a typical autologous cell immunotherapy, CAR T-cell therapy uses genetically modified T cells to express tumor-specific chimeric antigen receptors (CARs). Its targeting ability, persistent nature, and tumor-killing function result in a significant impact on the treatment of hematological tumors. However, no breakthrough has happened in the research specific to the curation of lung cancer, liver cancer, breast cancer, and other common solid tumors. In this context, a combination of molecular targeted therapy and CAR T-cell therapy was used to treat a patient with advanced HCC to achieve a partial remission(PR) and facilitate further liver transplantation.
format Online
Article
Text
id pubmed-10225497
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102254972023-05-30 Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report Wang, Yun Zhao, Yan Li, Miaoling Hou, Huilian Jian, Zhijie Li, Weizhi Li, Peijie Ma, Fuquan Liu, Mengying Liu, Haibo Xue, Hui Front Immunol Immunology Primary liver cancer (PLC) that originates in the liver is a malignant tumor with the worst prognosis. Hepatocellular carcinoma (HCC) is the most common type of PLC. Most PLC cases are diagnosed at advanced stages mainly due to their insidious onset and rapid progression. Patients with PLC undergo surgical intervention or localized treatment, but their survival is often affected by its high relapse rate. Medical treatment is the primary option for patients with liver cancer, especially with advanced extrahepatic metastases. Molecular targeted therapy exerts an anti-tumor effect by acting on various signaling pathways involved in molecular pathogenesis; however, high drug resistance and low therapeutic responsiveness of PLC to molecular targets challenge the treatment option. In recent years, after surgical intervention, radiotherapy, chemotherapy, and/or molecular targeted therapy, autologous cell immunotherapy has been adopted for PLC. As a typical autologous cell immunotherapy, CAR T-cell therapy uses genetically modified T cells to express tumor-specific chimeric antigen receptors (CARs). Its targeting ability, persistent nature, and tumor-killing function result in a significant impact on the treatment of hematological tumors. However, no breakthrough has happened in the research specific to the curation of lung cancer, liver cancer, breast cancer, and other common solid tumors. In this context, a combination of molecular targeted therapy and CAR T-cell therapy was used to treat a patient with advanced HCC to achieve a partial remission(PR) and facilitate further liver transplantation. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225497/ /pubmed/37256142 http://dx.doi.org/10.3389/fimmu.2023.1180001 Text en Copyright © 2023 Wang, Zhao, Li, Hou, Jian, Li, Li, Ma, Liu, Liu and Xue https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Yun
Zhao, Yan
Li, Miaoling
Hou, Huilian
Jian, Zhijie
Li, Weizhi
Li, Peijie
Ma, Fuquan
Liu, Mengying
Liu, Haibo
Xue, Hui
Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title_full Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title_fullStr Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title_full_unstemmed Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title_short Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report
title_sort conversion of primary liver cancer after targeted therapy for liver cancer combined with afp-targeted car t-cell therapy: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225497/
https://www.ncbi.nlm.nih.gov/pubmed/37256142
http://dx.doi.org/10.3389/fimmu.2023.1180001
work_keys_str_mv AT wangyun conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT zhaoyan conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT limiaoling conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT houhuilian conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT jianzhijie conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT liweizhi conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT lipeijie conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT mafuquan conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT liumengying conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT liuhaibo conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport
AT xuehui conversionofprimarylivercanceraftertargetedtherapyforlivercancercombinedwithafptargetedcartcelltherapyacasereport